A systematic review of cannabinoid use in inflammatory bowel disease found that most studies reported reduced symptoms and improved wellbeing, but high heterogeneity in study designs and dosing makes it impossible to determine the ideal approach.
IBD patients considering cannabis, gastroenterologists, medical cannabis researchers.
15-40% of IBD patients use cannabinoids, but optimal use remains undefined
What the researchers found
The majority of selected studies reported reduced clinical complications as measured by Mayo scores, CDAI, Lichtiger Index, and Harvey-Bradshaw Index, along with weight gain and improved patient wellbeing. However, outcomes were highly heterogeneous across study designs, disease activity measures, treatment durations, administration modes, and dosing protocols.
Why it matters
IBD patients increasingly use cannabis for symptom relief, and 15-40% of IBD patients worldwide report using cannabinoids. This review consolidates the evidence, confirming promising signals while honestly acknowledging that the research is too heterogeneous to guide clinical practice.
The numbers in context
15-40% of IBD patients worldwide use cannabis or cannabinoids. Most studies reported improvements in clinical indices (Mayo, CDAI, Harvey-Bradshaw, Lichtiger). High heterogeneity across all study parameters.
How the study worked
Systematic review following PRISMA guidelines, examining published research from 2012-2022 on cannabinoid use in IBD treatment. Assessed outcomes including clinical activity indices, symptom relief, and general wellbeing.
What this study cannot tell us
High heterogeneity in study designs, dosing, duration, administration routes, and outcome measures. Many included studies were small or observational. Generalizability limited by inconsistent methodology. Publication bias may favor positive results.
How to read the evidence
Systematic review with PRISMA methodology, but limited by high heterogeneity and lack of standardized trials in the underlying literature.
When this study was published
Published 2023, reviewing literature from 2012-2022.
The bigger picture
The disconnect between patient-reported benefits and the lack of high-quality evidence creates a challenging situation for clinicians. Patients are already using cannabinoids, but physicians cannot confidently recommend specific products, doses, or delivery methods. Standardized randomized controlled trials are urgently needed.
Questions still open
- What is the optimal cannabinoid formulation and dose for IBD?
- Do cannabinoids achieve objective mucosal healing or only symptomatic relief?
Common questions
Do cannabinoids help with inflammatory bowel disease?
How many IBD patients use cannabis?
Read the original research
The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature.
Cureus, 15(3), e36148
Citation
Nduma, Basil N; Mofor, Kelly A; Tatang, Jason; Ekhator, Chukwuyem; Ambe, Solomon; Fonkem, Ekokobe. (2023). The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature.. Cureus, 15(3), e36148. https://doi.org/10.7759/cureus.36148
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk